B
Brian D. Palmer
Researcher at University of Auckland
Publications - 119
Citations - 5132
Brian D. Palmer is an academic researcher from University of Auckland. The author has contributed to research in topics: Carboxamide & Bedaquiline. The author has an hindex of 39, co-authored 117 publications receiving 4658 citations. Previous affiliations of Brian D. Palmer include Pfizer.
Papers
More filters
Journal ArticleDOI
Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review.
TL;DR: P pH-responsive biomaterials bring forth conformational changes in these nanocarriers through various mechanisms such as protonation, charge reversal or cleavage of a chemical bond, facilitating tumour specific cell uptake or drug release, helping to design more efficient drug delivery systems.
Journal ArticleDOI
Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
Jeffrey Bruce Smaill,Brian D. Palmer,Gordon W. Rewcastle,William A. Denny,Dennis J. McNamara,Ellen M. Dobrusin,Alexander James Bridges,Zhou Hairong,H. D. H. Showalter,R. T. Winters,W. R. Leopold,David W. Fry,James M. Nelson,V. Slintak,W. L. Elliot,Bill J. Roberts,Patrick W. Vincent,S. J. Patmore +17 more
TL;DR: A series of 6- and 7-acrylamide derivatives of the 4-(phenylamino)quinazoline and -pyridopyrimidine classes of epidermal growth factor receptor (EGFR) inhibitors showed significant tumor growth inhibition (stasis) over a dose range, and the poor aqueous solubility of the compounds was a drawback.
Journal ArticleDOI
Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards.
TL;DR: Metal complexes of nitrogen mustards have significant hypoxic selectivity toward mammalian cells in cell culture and are a new general class of hypoxia-selective cytotoxins.
Journal ArticleDOI
Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor
Gordon W. Rewcastle,Brian D. Palmer,Alexander James Bridges,H. D. Hollis Showalter,Li Sun,James A. Nelson,Amy McMichael,Alan J. Kraker,David W. Fry,William A. Denny +9 more
TL;DR: Results are consistent with structure-activity relationship studies previously developed for the 4-[(3-bromophenyl)amino] quinazolines, which suggested that small electron-donating substituents at the 6- and 7-positions were desirable for high potency.
Journal ArticleDOI
Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.
Gordon W. Rewcastle,Brian D. Palmer,Andrew M. Thompson,Alexander James Bridges,Donna Reynolds Cody,Zhou Hairong,David W. Fry,and Amy McMichael,William A. Denny +8 more
TL;DR: Select compounds were evaluated for their ability to inhibit EGFR autophosphorylation in A431 cells, and a positive quantitative correlation was found between this activity and inhibitory activity against the isolated enzyme.